CLINICAL RESEARCH CENTER FOR THE STUDY OF SCHIZOPHRENIA

MHCRC将促进合作研究联系并发挥催化剂的作用 对于从事多学科研究的调查人员来说， 精神分裂症的脆弱性/应激概念。MHCRC的结构是 作为一组核心实验室提供评估、诊断、数据 管理、临床和行政服务提供给7个核心和几个 附属研究项目。MHCRC核心实验室包括家庭 评估和治疗，社交技能， 认知-心理生理学-神经心理学，临床精神药理学， 和诊断/精神病理学评估。实验室和单位进行 “研发”工作，并提供评估和诊断服务 自主资助的研究项目。由CORE开展的研究 实验室、单位和项目因共同的脆弱性/压力而团结在一起 精神分裂症的概念及多层次研究的指导 环境、心理和生物变量。个人内部 脆弱因素、人际和家庭调节和 增强因素，以及加速或加重症状的压力源 在关联性、互动性、治疗性和纵向方面进行评估 学习。这些研究的结果将提供复发和复发的信息 缓解并允许设计更有针对性的干预策略 精神分裂症的预防和治疗。阿司匹林的功效 至少三种创新的治疗方法，将心理社会和 药物治疗要素将被记录下来；社交技能培训和 经过验证的家庭治疗方法将被打包用于 在手册中传播。将制定程序来预测 复发风险高的患者，可能是 具体形式的家庭教育和治疗。我们会作出改善 在评估社交技能结构的技术方面。精神分裂症患者 将确定哪些患者得到了低剂量的最佳治疗 氟奋乃静和对试验剂量的早期反应的评估将是 用来预测他们的长期结果。纵向、多层次的研究 旨在阐明预测复发、缓解模式的变量 和生活质量；并传播标志着特征相似的变量 那些与精神分裂症症状有关的人的脆弱性。

The MHCRC will foster collaborative research ties and serve as a catalyst for investigators pursuing multidisciplinary research on a vulnerability/stress conception of schizophrenia. The MHCRC is structured as a set of core laboratories providing assessment, diagnostic, data management, clinical, and administrative services to 7 core and several affiliated research projects. Core MHCRC laboratories include family assessment and treatment, social skills, cognitive-psychophysiology-neuropsychology, clinical psychopharmacology, and diagnosis/psychopathology assessment. Laboratories and units conduct "R and D" work and offer assessment and diagnostic services to independently funded research projects. The research carried out by core laboratories, units and projects is united by a common vulnerability/stress conception of schizophrenia and guided by multilevel study of environmental, psychological, and biological variables. Intrapersonal vulnerability factors, interpersonal and familial moderating and potentiating factors, and stressors that precipitate or exacerbate symptoms are evaluated in correlational, interactional, treatment, and longitudinal studies. The results of these studies will give information on relapse and remission and permit the design of more focused intervention strategies for prevention and treatment of schizophrenic disorders. The efficacy of at least three innovative treatment methods that combine psychosocial and pharmacotherapy elements will be documented; social skills training and family therapy methods that have been validated will be "packaged" for dissemination in manuals. Procedures will be developed for predicting patients who are at high risk for relpase and would be candidates for specific forms of family education and therapy. Improvements will be made in technology for assessing the construct of social skills. Schizophrenic patients will be identified who are optimally treated with low dose, depot fluphenazine and evaluation of their early response to test doses will be used to predict their long-term outcome. A longitudinal, multilevel study aims to elucidate variables which predict patterns of relapse, remission and quality of life; and disseminate variables which mark trait-like vulnerability from those which are linked to symptoms of schizophrenia.